These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31095829)

  • 1. Impact of pharmaceutical industry involvement in the external review of clinical practice guidelines-A case study.
    Bartelmann K; Gaskins M; Dressler C; Nast A
    J Eval Clin Pract; 2020 Jun; 26(3):718-727. PubMed ID: 31095829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between authors of clinical practice guidelines and the pharmaceutical industry.
    Choudhry NK; Stelfox HT; Detsky AS
    JAMA; 2002 Feb; 287(5):612-7. PubMed ID: 11829700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
    Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observing expert opinion of medical affairs pharmaceutical physicians on the value of their clinical experience to the pharmaceutical industry using the Jandhyala method.
    Jandhyala R; Rout R
    Curr Med Res Opin; 2023 Dec; 39(12):1541-1550. PubMed ID: 36632732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines Authors.
    Checketts JX; Sims MT; Vassar M
    JAMA Dermatol; 2017 Dec; 153(12):1229-1235. PubMed ID: 29049553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient involvement in guidelines is poor five years after institute of medicine standards: review of guideline methodologies.
    Armstrong MJ; Bloom JA
    Res Involv Engagem; 2017; 3():19. PubMed ID: 29062544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of the pharmaceutical industry on treatment guidelines].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2429-31. PubMed ID: 18064860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
    Tyrawski J; DeAndrea DC
    J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument.
    Jandhyala R
    Pharmaceut Med; 2022 Feb; 36(1):47-57. PubMed ID: 34994965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early achievements of the Danish pharmaceutical industry-6 Pharmacia].
    Grevsen JV; Kruse E; Kruse PR
    Theriaca; 2014; (42):9-30. PubMed ID: 25816560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital Medical Information Services Delivered by Pharmaceutical Companies via WeChat: Qualitative Analytical Study.
    Ge Y; Yao D; Ung COL; Xue Y; Li M; Lin J; Hu H; Lai Y
    J Med Internet Res; 2023 Nov; 25():e43812. PubMed ID: 37976079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.